论文部分内容阅读
[目的]评价阿泰宁联合柳氮磺胺吡啶胶囊治疗溃疡性结肠炎的疗效和安全性。[方法]采用随机对照研究方法,将2008年1月～2009年4月收治的45例溃疡性结肠炎患者随机分为试验组和对照组,试验组使用阿泰宁(1.26g,3粒/d)联合柳氮磺胺吡啶胶囊(1g,4次/d)进行治疗,对照组使用柳氮磺胺吡啶胶囊治疗(1g,4次/d),疗程均为8周。[结果]试验组总有效率为78.26%,对照组总有效率为63.64%,两组差异有统计学意义(P﹤0.05)。[结论]阿泰宁联合柳氮磺胺吡啶胶囊对溃疡性结肠炎患者的疗效及安全性优于单用柳氮磺胺吡啶胶囊,复发率低。
[Objective] To evaluate the efficacy and safety of Artenin combined with sulfasalazine in the treatment of ulcerative colitis. [Methods] Forty-five patients with ulcerative colitis admitted to our hospital from January 2008 to April 2009 were randomly divided into experimental group and control group. Randomized controlled trial was conducted. Arterunin (1.26g, 3 capsules / d) were treated with sulfasalazine capsules (1g, 4 times / d), while the control group was treated with sulfasalazine capsules (1g, 4 times / d) for 8 weeks. [Results] The total effective rate was 78.26% in the experimental group and 63.64% in the control group, with significant difference between the two groups (P <0.05). [Conclusion] The efficacy and safety of Artenin combined with sulfasalazine capsules in patients with ulcerative colitis is better than that of sulfasalazine alone, with a low recurrence rate.